Early lupus patient data sends Kezar Life Sciences' stock soaring after-hours

The company's stock also took a substantial dive early last month after the same drug missed its mark in two other diseases.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.